Athenagen

Description

CoMentis, located in South San Francisco, is engaged in the discovery and development of new medicines to treat difficult neurovascular diseases. CoMentis’s development pipeline consists of: an oral α7 nAChR agonist in Phase II development for cognition enhancement; a non-invasive eyedrop therapy in Phase I development for age-related macular degeneration; small molecule inhibitors of the beta-secretase enzyme in late preclinical development for the treatment of Alzheimer’s disease; and a pro-angiogenic gel in Phase II development for treatment of non-healing wounds such as diabetic foot ulcers.

Companies nearby